HOOKIPA Pharma Inc.
HOOKDelisted Jul 29, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001760542
HOOKIPA Pharma Inc. was delisted on Jul 29, 2025; its insiders filed their last Form 4 on Oct 9, 2025; 27 institutions reported holding it in 13F filings for Q2 2025, worth $6.01M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 27
- Q2 2025, −5 vs. previous quarter
- 13F value
- $6.01M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding HOOK, Q2 2025
No superinvestor reported holding HOOK at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by HOOKIPA Pharma Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2025 (view filing) | Aug 19 | 51 daysLate | Peters MalteChief Executive Officer | SSale | −25.2K | $0.82 | −$20.6K | −31.7%54.3K after | |
| Jul 23, 2025 (view filing) | Jul 22 | 1 day | Peters MalteChief Executive Officer | SSale | −29.2K | $0.92 | −$26.8K | −26.8%79.5K after | |
| Jul 23, 2025 (view filing) | Jul 22 | 1 day | Coelho Mary TheresaEVP and CFO | SSale | −13.6K | $0.92 | −$12.5K | −19.5%56.3K after | |
| Aug 22, 2023 (view filing) | Aug 21 | 1 day | Kandera ReinhardChief Financial Officer | PPurchase | +7.00K | $0.73 | +$5.11K | +19.4%43.1K after | |
| Aug 17, 2023 (view filing) | Aug 16 | 1 day | Kandera ReinhardChief Financial Officer | PPurchase | +8.00K | $0.71 | +$5.68K | +28.5%36.1K after | |
| Jul 11, 2023 (view filing) | Jul 7-11 | 4 days | Aldag JornChief Executive Officer | PPurchase | +10.0K | $0.82 | +$8.20K | +16.1%72.0K after | 2 lots |
| Jul 7, 2023 (view filing) | Jul 5 | 2 days | Aldag JornChief Executive Officer | PPurchase | +5.00K | $0.89 | +$4.45K | +8.8%62.0K after | |
| Jul 5, 2023 (view filing) | Jul 3 | 2 days | Aldag JornChief Executive Officer | PPurchase | +5.00K | $0.89 | +$4.45K | +9.6%57.0K after | |
| Jul 3, 2023 (view filing) | Jun 30 | 3 days | Kandera ReinhardChief Financial Officer | PPurchase | +12.0K | $0.88 | +$10.6K | +74.6%28.1K after | |
| Jan 12, 2022 (view filing)10:07 AM ET | Dec 21, 2021 | 22 daysLate | Matushansky IgorChief Medical Officer | SSale | −14.9K | $2.49 | −$37.2K | −14.9%85.3K after | 3 lots |
Top 10 13F holders, Q2 2025
The largest institutional positions in HOOKIPA Pharma Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 1,875,945 | $2.35M | 0.18% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 812,814 | $1.02M | 0.01% | 00.0% | Unchanged |
| Siren, L.L.C. | 566,640 | $711.1K | 0.04% | 00.0% | Unchanged |
| Knoll Capital Management, LLC | 498,625 | $625.8K | 0.44% | 00.0% | Unchanged |
| FMR LLC | 334,030 | $419.2K | 0.00% | −15,737−4.5% | Reduced |
| Vanguard Group Inc | 300,819 | $377.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 73,341 | $92.1K | 0.00% | −91−0.1% | Reduced |
| Acadian Asset Management LLC | 55,735 | $69.0K | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 52,996 | $66.5K | 0.02% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 45,570 | $57.2K | 0.00% | +4,600+11.2% | Added |